There are 2867 resources available
LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
Presenter: Christian Rothermundt
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Lessons learned and new horizons for treatment of primary brain tumours
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: What’s old is new again
Resources:
Webcast
Discussion
Presenter: All Speakers
Session: New classification and staging of breast cancer
Resources:
Slides
Webcast
Invited Discussant 314O and LBA23
Presenter: Andrea Cercek
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Slides
Webcast
Conclusion and closing remarks
Presenter: Lena Sharp
Session: In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe
Resources:
Webcast
Biliary tract cancer: Clinical case
Presenter: Elene Mariamidze
Session: ESMO Clinical Practice Guidelines session 1
Resources:
Slides
Webcast
973MO - KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
Presenter: Marina Garassino
Session: Mini Oral session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Presenter: Evan Yu
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1: GI, lower digestive
Resources:
Slides
Webcast